Search
MoonLake Immunotherapeutics
MLTXAdd to Watchlist
19.100USD
-0.030-0.16%
Market hours （ET）Quotes delayed by 15 min
1.36BMarket Cap
LossP/E TTM
More Details of MoonLake Immunotherapeutics Company
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics Info
Ticker SymbolMLTX
Company nameMoonLake Immunotherapeutics
IPO dateOct 20, 2020
CEOSantos Da Silva (Jorge)
Number of employees100
Security typeOrdinary Share
Fiscal year-endOct 20
AddressDorfstrasse 29
CityZUG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code6300
Phone41415108022
Websitehttps://moonlaketx.com/
Ticker SymbolMLTX
IPO dateOct 20, 2020
CEOSantos Da Silva (Jorge)
Company Executives of MoonLake Immunotherapeutics
Name
Name/Position
Position
Shareholding
Change
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.01M
+1.63%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
1.12M
-5.11%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
FAQs
Who are the top five shareholders of MoonLake Immunotherapeutics?
The top five shareholders of MoonLake Immunotherapeutics are: Dr. Kristian Reich
How many institutions hold shares of MoonLake Immunotherapeutics (MLTX)?
As of 2026Q1, 358 institutions hold shares of MoonLake Immunotherapeutics, with a combined market value of approximately 54.44M, accounting for 74.73% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3151979.00.